Analysts at Goldman (GS) downgraded Myriad Genetics Inc. (MYGN) from ‘Neutral‘ to ‘Sell‘ in a research report issued to clients on Thursday.
The target price for MYGN is lowered from $31 to $25, implying 19% downside.
On valuation measures, Myriad Genetics Inc. stock it’s trading at a forward P/E multiple of 18.35x, and at a multiple of 24.44x this year’s estimated earnings. The t-12-month revenue at Myriad Genetics is $724.92 million. MYGN ‘s ROE for the same period is 16.12%.
Shares of the $2.51 billion market cap company are up 5.20% year-over-year and 6.28% year-to-date.
Myriad Genetics Inc., currently with a median Wall Street price target of $33.00 and a high target of $50.00, dropped $0.83 to $35.36 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
SanDisk Corp. (SNDK) was downgraded from ‘Buy‘ to ‘Neutral‘ at Bank of America (BAC) following the chipmaker’s revised revenue guidance for Q1 (Mar) to $1.3 billion, down 13% from the year-earlier quarter and below its prior guidance of $1.4 billion – $1.45 billion.
Shares have traded today between $65.45 and $71.50 with the price of the stock fluctuating between $65.45 to $108.77 over the last 52 weeks.
SanDisk Corp. shares are currently changing hands at 15.60x this year’s forecasted earnings, compared to the industry’s 25.67x earnings multiple. Ticker has a t-12 price/sales ratio of 2.61. EPS for the same period registers at $4.23.
Shares of SNDK have lost $15.18 to $66.00 in mid-day trading on Thursday, giving it a market cap of roughly $14.06 billion. The stock traded as high as $108.77 in July 16, 2014.
Goldman (GS) reported on Thursday that they have lowered their rating for Exact Sciences Corporation (EXAS). The firm has downgraded EXAS from ‘Buy‘ to ‘Neutral‘ and lowered its price target to $24 from $29.
Exact Sciences Corp. recently traded at $21.32, a loss of $1.74 over Wednesday’s closing price. The name has a current market capitalization of $1.89 billion.